Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718240 | 0.93 | CHRM2 (0.55) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 | |
| SCHEMBL636999 | 0.89 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL4870895 | 0.87 | CHRM2 (0.60) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| Ammonia Solution, Strong SCHEMBL8187341 | 0.85 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL1723411 | 0.85 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL5728905 | 0.85 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL3082036 | 0.81 | CHRM2 (0.47) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL3083479 | 0.81 | CHRM2 (0.47) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL3076478 | 0.81 | CHRM2 (0.47) | CHRM2CHRM4CHRM5LMNAKMT2A | |
| SCHEMBL3311708 | 0.81 | CHRM2 (0.54) | CHRM2CHRM4CHRM5LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507482-B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120122861-A1 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8168632-B2 | Bicyclic amide derivatives for the treatment of respiratory disorders | CORTEX PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8119632-B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2391621-A2 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010087980-A2 | BICYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DEPRESSION | CORTEX PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010087981-A2 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100173903-A1 | Bicyclic amide derivatives for the treatmet of respiratory disorders | CORTEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173902-A1 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICAL, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2009055331-A2 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-1546147-A1 | MORPHOLINE-BRIDGED INDAZOLE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004031186-A1 | MORPHOLINE-BRIDGED INDAZOLE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1406908-A1 | MORPHOLINE-BRIDGED PYRAZOLOPYRIDINE DERIVATIVES | Bayer HealthCare AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004503-A1 | MORPHOLINE-BRIDGED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | OPRM1, OPRK1, OPRD1 | CHRM2 140/4885CHRM4 132/4885CHRM5 27/4885 |
| US-20120122861-A1 | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN1, GRIN2A, BDNF | CHRM2 115/4885CHRM4 114/4885CHRM5 136/4885 |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | GUCY1B2, COG4, GUCY1A2 | CHRM2 108/4885CHRM4 6/4885CHRM5 14/4885 |
| US-20100173903-A1 | Bicyclic amide derivatives for the treatmet of respiratory disorders | ABAT, COX6A1, OAT | CHRM2 155/4885CHRM4 304/4885CHRM5 243/4885 |
| US-20100173902-A1 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | HCRTR2, CHAT, GRIN1 | CHRM2 154/4885CHRM4 428/4885CHRM5 442/4885 |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | GUCY1A1, PDE1A, PDE3B | CHRM2 292/4885CHRM4 602/4885CHRM5 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.